Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from DLBCL tumor biopsies and TMD8 cell line

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE93986 | GEO | 2017/04/30

SECONDARY ACCESSION(S): PRJNA363005

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from DLBCL tumor biopsies and TMD8 cell line

Project description:Expression data from DLBCL tumor biopsies and TMD8 cell line

| PRJNA363005 | ENA

MicroRNAs and gene expression profiles of rapamycin sensitive and resistant myogenic tumor cell line

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-02-08 | E-GEOD-19944 | biostudies-arrayexpress

Expression data from pancreatic stellate cells and cancer cell line MiaPaca2

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-08-09 | E-GEOD-49588 | biostudies-arrayexpress

IkB-like protein NFKBIZ regulates NF-kB signaling and is critical for survival of ABC DLBCL

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-07-22 | E-GEOD-46974 | biostudies-arrayexpress

microRNA profile of DLBCL

Project description:This SuperSeries is composed of the SubSeries listed below.

2009-03-16 | GSE15225 | GEO

Expression data from DLBCL tumor biopsies

Project description:Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the most prevalent B-lymphocyte neoplasms in which abnormal activation of the Bruton’s tyrosine kinase (BTK)–mediated B-cell receptor (BCR) signaling pathway contributes to pathogenesis. Ibrutinib is an oral covalent BTK inhibitor that has shown some efficacy in both indications. To improve ibrutinib efficacy through combination therapy, we first investigated differential gene expression in parental and ibrutinib-resistant cell lines to better understand the mechanisms of resistance. Ibrutinib-resistant TMD8 cells had higher BCL2 gene expression and increased sensitivity to ABT-199, a BCL-2 inhibitor. Consistently, clinical samples from ABC-DLBCL patients who experienced poorer response to ibrutinib had higher BCL2 gene expression. We further demonstrated synergistic growth suppression by ibrutinib and ABT-199 in multiple ABC-DLBCL, GCB-DLBCL, and FL lymphoma cell lines. The combination of both drugs also reduced colony formation, increased apoptosis, and inhibited tumor growth in a TMD8 xenograft model. A synergistic combination effect was also found in ibrutinib-resistant cells generated by either genetic mutation or drug treatment. Together, these findings suggest a potential clinical benefit from ibrutinib and ABT-199 combination therapy.

2017-04-30 | GSE93984 | GEO

Expression data and Copy Number Variations from Diffuse Large B Cell Lymphoma (DLBCL) patients

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-09-05 | GSE136971 | GEO

microRNA and mRNA expression in human hepatitis C Virus liver biopsies

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series This dataset is part of the TransQST collection.

2010-03-08 | E-GEOD-15387 | biostudies-arrayexpress

Expression data from Glioblastoma Multiforme patient tumor samples, healthy brain tissue (partly from GBM patients) and NHA cell line and Human fetal astrocyte cell line

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-09-15 | GSE90604 | GEO

DNA methylation status is more sensitive than gene expression at detecting cancer in prostate core biopsies

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-07-01 | E-GEOD-55599 | biostudies-arrayexpress